Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Applied Health Economics and Health Policy
Published in: Applied Health Economics and Health Policy 2/2016

01-04-2016 | Scoping Review

A Scoping Review of Healthcare Costs for Patients with Cystic Fibrosis

Authors: Ilene L. Hollin, Karen A. Robinson

Published in: Applied Health Economics and Health Policy | Issue 2/2016

Login to get access

Abstract

Background

Cystic fibrosis (CF), one of the most common life-shortening genetic diseases, has no cure, but people living with it have seen improvements in their health and survival. The rising life expectancy and increased availability of treatment options has likely increased the lifetime costs of people living with CF. In addition, a recent drug approval for a therapy that targets the cause of the disease is one of the most expensive drugs worldwide. In light of these circumstances, it is important to have an updated understanding of the costs of CF therapy and management. This study aims to determine the extent of available literature that quantifies CF costs.

Methods

We used a scoping review framework to identify the sources and types of evidence available to determine the costs of CF therapy and management compared to the general population or a comparable population of people with other complex chronic conditions. We searched 14 databases for peer-reviewed studies and grey literature published in English since 1998. The search was conducted in August 2013 and updated in October 2014.

Results

We identified 28 studies that estimated overall, general CF costs. Of these, three studies compare CF costs to healthcare costs of a general population and only one of those provides a direct comparison of CF costs to the general population in order to calculate the incremental cost associated with CF. We estimate there are 98 systematic reviews that quantify the costs of comparable conditions and potentially provide a comparison group for people with CF.

Conclusions

There is evidence available that attempts to quantify overall, general healthcare costs of people with CF, although much of it is outdated. However, there is much less evidence available that provides a comparison of these costs with either the general population or people with comparable conditions.
Appendix
Available only for authorised users
Literature
1.
Cystic Fibrosis Foundation. Cystic Fibrosis Foundation Patient Registry 2012 Annual Data Report. Bethesda, MD; 2013.
2.
Cohen-Cymberknoh M, Shoseyov D, Kerem E. Managing cystic fibrosis: strategies that increase life expectancy and improve quality of life. Am J Respir Crit Care Med. 2011;183:1463–71.CrossRefPubMed
3.
4.
Arksey H, O’Malley L. Scoping studies: towards a methodological framework. Int J Soc Res Methodol. 2005;8(1):19–32.CrossRef
5.
Colquhoun H, Levac D, O’Brien KK, Straus S, Tricco AC, Perrier L, et al. Scoping reviews: time for clarity in definition, methods, and reporting. J Clin Epidemiol. 2014;67(12):1291–4.CrossRefPubMed
6.
7.
Davidoff AJ. Insurance for children with special health care needs: patterns of coverage and burden of families to provide adequate insurance. Pediatrics. 2004;114(2):394–402.CrossRefPubMed
8.
Druss BG, Marcus SC, Olfson M, Tanielian T, Elinson L, Pincus HA. Comparing the national economic burden of five chronic conditions. Health Aff. 2001;20(6):233–41.CrossRef
9.
Health Resources and Services Administration, Maternal and Child Health Bureau Conducted by the National Center for Health Statistics, Centers for Disease Control and Prevention. (2009–2010) National survey of children with special health care needs. Questionnaire Version: December 14, 2011.
10.
Chen AY, Newacheck PW. Insurance coverage and financial burden for families of children with special health care needs. Ambul Pediatr. 2006;6(4):204–9.CrossRefPubMedPubMedCentral
11.
Ramsey BW, Pepe MS, Quan JM, Otto KL, Montgomery AB, Williams-Warren J, et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group. NEJM. 1999;340(1):23–30.CrossRefPubMed
12.
Woodward TC, Brown R, Sacco P, Zhang J. Budget impact model of tobramycin inhalation solution for treatment of Pseudomonas aeruginosa in cystic fibrosis patients. J Med Econ. 2010;13(3):492–9.CrossRefPubMed
13.
Colombo C, Dacco V, Loi S, Anelli M, Alicandro G. Analysis of cost drivers for health care services use in cystic fibrosis patients: the experience of the Milan cystic fibrosis center. J Cyst Fibros. 2014;13:S104.CrossRef
14.
Strong M, Harr B. Burden of disease and out-of-pocket costs associated with CF for patients and caregivers in the United States. Pediatr Pulmonol. 2010;45:447–8.
15.
Krauth C, Jalilvand N, Welte T, Busse R. Cystic fibrosis: cost of illness and considerations for the economic evaluation of potential therapies. Pharmacoeconomics. 2003;21(14):1001–24.CrossRefPubMed
16.
Balinsky W, Zhu CW. Pediatric cystic fibrosis: evaluating costs and genetic testing. J Pediatr Health Care. 2004;18(1):30–4.CrossRefPubMed
17.
Lieu TA, Ray GT, Farmer G, Shay GF. The cost of medical care for patients with cystic fibrosis in a health maintenance organization. Pediatrics. 1999;103(6):e72.CrossRefPubMed
18.
Ouyang L, Grosse SD, Amendah DD, Schechter MS. Healthcare expenditures for privately insured people with cystic fibrosis. Pediatr Pulmonol. 2009;44(10):989–96.CrossRefPubMed
19.
Baumann U, Stocklossa C, Greiner W, von der Schulenburg JM, von der Hardt H. Cost of care and clinical condition in paediatric cystic fibrosis patients. J Cyst Fibros. 2003;2(2):84–90.CrossRefPubMed
20.
Becker CC, Clements K, DeLong K, Harrow B, O’Sullivan A. Economic burden of cystic fibrosis in the US: costs of care by disease severity and age. Value Health. 2011;14(7):A490.CrossRef
21.
Briesacher BA, Quittner AL, Fouayzi H, Zhang J, Swensen A. Nationwide trends in the medical care costs of privately insured patients with cystic fibrosis (CF), 2001–2007. Pediatr Pulmonol. 2011;46(8):770–6.CrossRefPubMed
22.
Broder MS, Nasr SZ, Chang E, Villa KF. Utilization and healthcare charges in an insured US cystic fibrosis (CF) patient population. J Cyst Fibros. 2011;10:S97.CrossRef
23.
Colombo C, Daccò V, Alicandro G, Loi S, Mazzi S, Lucioni C, et al. Cost of cystic fibrosis: analysis of treatment costs in a specialized center in Northern Italy. Adv Ther. 2013;30(2):165–75.CrossRefPubMed
24.
Dewitt EM, Grussemeyer CA, Friedman JY, Dinan MA, Lin L, Schulman KA, Reed SD. Resource use, costs, and utility estimates for patients with cystic fibrosis with mild impairment in lung function: analysis of data collected alongside a 48-week multicenter clinical trial. Value Health. 2012;15(2):277–83.CrossRefPubMed
25.
Eakin MN, Bilderback A, Ridge A, Quittner AL, Zhang J, Riekert KA. Out-of-pocket costs for medications in the I change adherence and raise expectations (iCARE) study. Pediatr Pulmonol. 2011;46:420.
26.
Gu Y, Garcia-Perez S, Massie J, van Gool K. Cost of care for cystic fibrosis: an investigation of cost determinants using national registry data. Eur J Health Econ. 2015;16(7):709–17.CrossRefPubMed
27.
Harrow B, Becker CC, Buikema A. High cost cystic fibrosis patients as identified in a us claims database: a closer look at the tail. Value Health. 2011;14(7):A491.CrossRef
28.
Heimeshoff M, Hollmeyer H, Schreyogg J, Tiemann O, Staab D. Cost of illness of cystic fibrosis in Germany: results from a large cystic fibrosis centre. Pharmacoeconomics. 2012;30(9):763–77.CrossRefPubMed
29.
Huot L, Durieu I, Bourdy S, Ganne C, Bellon G, Colin C, et al. Evolution of costs of care for cystic fibrosis patients after clinical guidelines implementation in a French network. J Cyst Fibros. 2008;7(5):403–8.CrossRefPubMed
30.
Jarrett J, Lies R, Mugford M, Legh-Smith J. The cost of paediatric cystic fibrosis to the NHS in the Eastern Region. J Cyst Fibros. 2008;7:S117.CrossRef
31.
Klimes J, Dolezal T, Vavrova V, Turnovec M, Skalicka V, Mlcoch T. Economic burden of cystic fibrosis (CF): prevalence based cost of illness analysis related to the lung disease severity in Czech CF patients. J Cyst Fibros. 2014;13:S11.CrossRef
32.
Levy J, Rosenberg M, Farrell PM. The direct medical costs of pediatric cystic fibrosis. Pediatr Pulmonol. 2013;48:375.
33.
O’Sullivan A, Sullivan J, Higuchi K, Montgomery A. Health care utilization and costs for cystic fibrosis patients with pulmonary infections. Manag Care. 2011;20(2):37–44.PubMed
34.
Okumura MJ, Campbell AD, Nasr SZ, Davis MM. Inpatient health care use among adult survivors of chronic childhood illnesses in the United States. Arch Pediatr Adolesc Med. 2006;160(10):1054–60.CrossRefPubMed
35.
Rosenberg MA, Farrell PM. Assessing the cost of cystic fibrosis diagnosis and treatment. J Pediatr. 2005;147(3 Suppl):S101–5.CrossRefPubMed
36.
Sansgiry S, Joish V, Boklage S, Goyal RK, Seal B, Sethi S. Pseudomonas aeruginosa related economic burden stratified by comorbidity in cystic fibrosis patients. Value Health. 2010;13(7):A433.CrossRef
37.
Sansgiry SS, Joish V, Boklage S, Goyal RK, Sethi S. Impact of pseudomonas aeruginosa infections on direct medical costs among cystic fibrosis patients. Pediatr Pulmonol. 2010;45:451.
38.
Sansgiry SS, Joish VN, Boklage S, Goyal RK, Chopra P, Sethi S. Economic burden of Pseudomonas aeruginosa infection in patients with cystic fibrosis. J Med Econ. 2012;15(2):219–24.CrossRefPubMed
39.
Schwerner H, Mellody T, Goldstein AB, Wansink D, Sullivan V, Yelenik SN, et al. Evaluating the impact of a disease management program for chronic complex conditions at two large northeast health plans using a control group methodology. Dis Manag. 2006;9(1):34–44.CrossRefPubMed
40.
van Gool K, Norman R, Delatycki MB, Hall J, Massie J. Understanding the costs of care for cystic fibrosis: an analysis by age and health state. Value Health. 2013;16(2):345–55.CrossRefPubMed
41.
Zhang J, Marynchenko M, Chopra P, Ohashi E, Signorovitch J, Wu E. Annual healthcare costs for patients with cystic fibrosis from a medicaid perspective. Pediatr Pulmonol. 2012;47:443–4.
42.
Johnson JA, Connolly MA, Jacobs P, Montgomery M, Brown NE, Zuberbuhler P. Cost of care for individuals with cystic fibrosis: a regression approach to determining the impact of recombinant human DNase. Pharmacotherapy. 1999;19(10):1159–66.CrossRefPubMed
43.
Cystic Fibrosis Foundation Patient Registry 2013 Annual Data Report to the Center Directors. In. Bethesda, MD: Cystic Fibrosis Foundation; 2014.
Metadata
Title
A Scoping Review of Healthcare Costs for Patients with Cystic Fibrosis
Authors
Ilene L. Hollin
Karen A. Robinson
Publication date
01-04-2016
Publisher
Springer International Publishing
Published in
Applied Health Economics and Health Policy / Issue 2/2016
Print ISSN: 1175-5652
Electronic ISSN: 1179-1896
DOI
https://doi.org/10.1007/s40258-015-0211-4

Other articles of this Issue 2/2016

Applied Health Economics and Health Policy 2/2016 Go to the issue

Letter to the Editor

Comment on: “The Role of Chronic Disease, Obesity, and Improved Treatment and Detection in Accounting for the Rise in Healthcare Spending Between 1987 and 2011”

Book Review

A Review of “The New Drug Reimbursement Game: A Regulator’s Guide to Playing and Winning”

Current Opinion

The Missing Stakeholder Group: Why Patients Should be Involved in Health Economic Modelling

Systematic Review

A Systematic Review of the Literature on the Development of Condition-Specific Preference-Based Measures of Health

Original Research Article

The Long-Term Cost to the UK NHS and Social Services of Different Durations of IV Thiamine (Vitamin B1) for Chronic Alcohol Misusers with Symptoms of Wernicke’s Encephalopathy Presenting at the Emergency Department

Original Research Article

Formal Professional Relationships Between General Practitioners and Specialists in Shared Care: Possible Associations with Patient Health and Pharmacy Costs